Taysha Gene Therapies, Inc. (TSHA)
5.355
-0.08
(-1.38%)
USD |
NASDAQ |
Jun 09, 16:00
5.30
-0.06
(-1.03%)
After-Hours: 20:00
Taysha Gene Therapies SG&A Expense (Quarterly) : 9.677M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| BioCryst Pharmaceuticals, Inc. | 94.55M |
| Agenus, Inc. | 6.86M |
| Amgen, Inc. | 1.602B |
| Imunon, Inc. | 1.969M |
| Curis, Inc. | 5.07M |